Full Press Release Details
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business
BASEL, LONDON, and NEW YORK, June 28, 2023 - Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.
Roivant's Chief Executive Officer, Matt Gline, noted: "I'm incredibly pleased with the progress we've made in recent months. Last week,
we reported RVT-3101 data from the chronic period of TUSCANY-2, our Phase 2b study in ulcerative colitis. These data surpassed our expectations, demonstrating improvement from the induction period at week 14 to the chronic period at week 56 across
all key efficacy endpoints for patients treated with the expected Phase 3 dose. In addition, earlier this spring we announced positive topline results for VTAMA's ADORING 1 and ADORING 2 Phase 3 trials in atopic dermatitis. The results reported
across both studies showed efficacy comparable to that of many systemic products, and we feel VTAMA has the potential to be a safe and efficacious topical option for adults and children as young as 2 years old. Finally, we reported strong growth in
VTAMA revenue this past quarter in psoriasis with over 75% of US commercial lives now covered. These recent developments, combined with our strong balance sheet, continue to support Roivant's growing leadership in the treatment of immunological and
inflammatory disease, and we are proud of our continued track record in clinical execution."
Major Upcoming Milestones
Matt Gline added: "I am incredibly pleased to welcome Meghan FitzGerald to our Board of Directors. Meghan's deep expertise in healthcare
and her extraordinary commitment to patients will be invaluable to Roivant's mission to accelerate the development and commercialization of medicines that matter."
Fourth Quarter and Fiscal Year Ended March 31, 2023,
As of March 31, 2023, the company had cash, cash equivalents and restricted cash of approximately $1.7 billion.
Research and Development Expenses
Research and development (R&D) expenses decreased by $3.2 million to $131.9 million for the three months ended March 31, 2023, compared
to $135.1 million for the year ended March 31, 2022, primarily due to decreases in share-based compensation of $11.9 million and other expenses of $3.7 million, partially offset by an increase in program specific costs of $12.3 million, largely
driven by the anti-FcRn franchise.
Non-GAAP R&D expenses were $126.0 million for the three months ended March 31, 2023, compared to $117.8 million for the three months
ended March 31, 2022.
R&D expenses increased by $42.2 million to $525.2 million for the year ended March 31, 2023, compared to $483.0 million for the year
ended March 31, 2022, primarily due to increases in program-specific costs of $45.8 million and personnel-related expenses of $28.1 million, partially offset by a decrease in share-based compensation of $32.8 million. The increase of $45.8 million
in program-specific costs largely reflects the progression of our programs and drug discovery, including the anti-FcRn franchise, RVT-2001, brepocitinib, and RVT-3101. The asset acquisitions of brepocitinib, RVT-2001, and RVT-3101 were completed in
September 2021, November 2021, and November 2022, respectively. Increases in program-specific costs were partially offset by certain decreases, including $19.3 million for tapinarof, which was primarily due to the completion of ADORING 1 and
ADORING 2 phase 3 atopic dermatitis clinical trials during the year ended March 31, 2023. The increase of $28.1 million in personnel-related expenses largely reflects the progression of our programs, particularly the anti-FcRn franchise. The
decrease of $32.8 million in share-based compensation expense was primarily due to the achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination in September 2021, resulting in
the recognition of a one-time catch-up expense of $22.9 million relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination and continued recognition of expense over the
requisite service periods.
Non-GAAP R&D expenses were $489.2 million for the year ended March 31, 2023, compared to $416.1 million for the year ended March 31,
Acquired In-Process Research and Development Expenses
There was no acquired in-process research and development (IPR&D) expense for the three months ended March 31, 2023. Acquired IPR&D
expenses were $1.5 million for the three months ended March 31, 2022.
Acquired IPR&D expenses decreased by $42.1 million to $97.7 million for the year ended March 31, 2023, compared to $139.9 million for
the year ended March 31, 2022. The decrease was primarily due to higher consideration for the purchase of IPR&D during the year ended March 31, 2022 as a result of consideration for the purchase of IPR&D of $82.1 million relating to the
acquisition of brepocitinib, a one-time milestone expense of approximately $39 million due to the achievement of a development milestone related to tapinarof, and consideration for the purchase of IPR&D of $14.1 million relating to the
acquisition of RVT-2001. Acquired IPR&D expenses for the year ended March 31, 2023, was driven by consideration for the purchase of IPR&D of $87.7 million relating to the
acquisition of RVT-3101 and the achievement of a development milestone relating to batoclimab, which resulted in a one-time milestone expense of $10.0 million.
Selling, General and Administrative Expenses
Selling, general and administrative (SG&A) expenses decreased by $13.5 million to $125.5 million for the three months ended March 31,
2023, compared to $139.0 million for the three months ended March 31, 2022. The decrease was primarily due to a decrease in share-based compensation of $40.0 million, partially offset by higher SG&A expenses at Dermavant as a result of the
commercial launch of VTAMA.
Non-GAAP SG&A expenses were $102.6 million for the three months ended March 31, 2023, compared to $77.3 million for the three months
ended March 31, 2022.
SG&A expenses decreased by $174.5 million to $600.5 million for the year ended March 31, 2023, compared to $775.0 million for the year
ended March 31, 2022. The decrease was primarily due to a decrease in share-based compensation expense of $314.6 million, partially offset by higher SG&A expenses at Dermavant as a result of the commercial launch of VTAMA. The decrease in
share-based compensation resulted from the achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination in September 2021, resulting in the recognition of a one-time catch-up
expense of $350.0 million for the year ended March 31, 2022, for cumulative service rendered between the grant date of the respective awards and completion of the Business Combination.
Non-GAAP SG&A expenses were $407.6 million for the year ended March 31, 2023, compared to $271.1 million for the year ended March 31,
Loss from Continuing Operations
Loss from continuing operations was $175.4 million for the three months ended March 31, 2023, compared to $291.3 million for the three
months ended March 31, 2022. On a per common share basis, loss from continuing operations was $0.20 for the three months ended March 31, 2023, and $0.39 for the three months ended March
31, 2022. Non-GAAP loss from continuing operations was $189.4 million for the three months ended March 31, 2023, compared to $187.7 million for the three months ended March 31, 2022.
Loss from continuing operations was approximately $1.2 billion for the year ended March 31, 2023, compared to $924.1 million for the year
ended March 31, 2022. On a per common share basis, loss from continuing operations was $1.58 for the year ended March 31, 2023, and $1.26 for the year ended March 31, 2022. Non-GAAP
loss from continuing operations was $924.3 million for the year ended March 31, 2023, compared to $784.2 million for the year ended March 31, 2022.
ROIVANT SCIENCES LTD.
Selected Balance Sheet Data
| March 31, 2023 | March 31, 2022 | |||||||
| Cash, cash equivalents and restricted cash | $ | 1,692,115 | $ | 2,074,034 | ||||
| Total assets | 2,389,604 | 2,585,129 | ||||||
| Total liabilities | 782,017 | 523,695 | ||||||
| Total shareholders' equity | 1,607,587 | 2,038,943 | ||||||
| Total liabilities, redeemable noncontrolling interest and shareholders' equity | 2,389,604 | 2,585,129 |
ROIVANT SCIENCES LTD.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | Years Ended March 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue, net | $ | 13,657 | $ | - | $ | 28,011 | $ | - | ||||||||
| License, milestone and other revenue | 13,719 | 9,223 | 33,269 | 55,286 | ||||||||||||
| Revenue, net | 27,376 | 9,223 | 61,280 | 55,286 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenues | 4,175 | 459 | 13,128 | 8,966 | ||||||||||||
| Research and development (includes $4,366 and $16,294 of share-based compensation expense for the three months ended March 31, 2023 and 2022, respectively, and $30,914 and $63,735 of share-based compensation expense for the years ended March 31, 2023 and 2022, respectively) | 131,857 | 135,077 | 525,215 | 483,035 | ||||||||||||
| Acquired in-process research and development | - | 1,517 | 97,749 | 139,894 | ||||||||||||
| Selling, general and administrative (includes $20,832 and $60,865 of share-based compensation expense for the three months ended March 31, 2023 and 2022, respectively, and $186,603 and $501,221 of share-based compensation expense for the years ended March 31, 2023 and 2022, respectively) | 125,510 | 138,973 | 600,506 | 775,033 | ||||||||||||
| Total operating expenses | 261,542 | 276,026 | 1,236,598 | 1,406,928 | ||||||||||||
| Loss from operations | (234,166 | ) | (266,803 | ) | (1,175,318 | ) | (1,351,642 | ) | ||||||||
| Change in fair value of investments | (32,462 | ) | 72,909 | 20,815 | 87,291 | |||||||||||
| Gain on sale of investment | - | - | - | (443,754 | ) | |||||||||||
| Change in fair value of debt and liability instruments | (12,031 | ) | (44,101 | ) | 78,001 | (3,354 | ) | |||||||||
| Gain on termination of Sumitomo Options | - | - | - | (66,472 | ) | |||||||||||
| Gain on deconsolidation of subsidiaries | - | (5,041 | ) | (29,276 | ) | (5,041 | ) | |||||||||
| Interest income | (14,284 | ) | (170 | ) | (32,184 | ) | (369 | ) | ||||||||
| Interest expense | 8,575 | 1,475 | 27,968 | 7,041 | ||||||||||||
| Other income, net | (4,748 | ) | (399 | ) | (15,808 | ) | (3,237 | ) | ||||||||
| Loss from continuing operations before income taxes | (179,216 | ) | (291,476 | ) | (1,224,834 | ) | (923,747 | ) | ||||||||
| Income tax expense | (3,793 | ) | (163 | ) | 5,190 | 369 | ||||||||||
| Loss from continuing operations, net of tax | (175,423 | ) | (291,313 | ) | (1,230,024 | ) | (924,116 | ) | ||||||||
| Income from discontinued operations, net of tax | 114,561 | - | 114,561 | - | ||||||||||||
| Net loss | (60,862 | ) | (291,313 | ) | (1,115,463 | ) | (924,116 | ) | ||||||||
| Net loss attributable to noncontrolling interests | (27,245 | ) | (21,251 | ) | (106,433 | ) | (78,854 | ) | ||||||||
| Net loss attributable to Roivant Sciences Ltd. | $ | (33,617 | ) | $ | (270,062 | ) | $ | (1,009,030 | ) | $ | (845,262 | ) | ||||
| Amounts attributable to Roivant Sciences Ltd.: | ||||||||||||||||
| Loss from continuing operations, net of tax | $ | (148,178 | ) | $ | (270,062 | ) | $ | (1,123,591 | ) | $ | (845,262 | ) | ||||
| Income from discontinued operations, net of tax | 114,561 | - | 114,561 | - | ||||||||||||
| Net loss attributable to Roivant Sciences Ltd. | $ | (33,617 | ) | $ | (270,062 | ) | $ | (1,009,030 | ) | $ | (845,262 | ) | ||||
| Basic and diluted net (loss) income per common share: | ||||||||||||||||
| Basic and diluted loss from continuing operations | $ | (0.20 | ) | $ | (0.39 | ) | $ | (1.58 | ) | $ | (1.26 | ) | ||||
| Basic and diluted income from discontinued operations | $ | 0.15 | $ | - | $ | 0.16 | $ | - | ||||||||
| Basic and diluted net loss per common share | $ | (0.05 | ) | $ | (0.39 | ) | $ | (1.42 | ) | $ | (1.26 | ) | ||||
| Basic and diluted weighted average shares outstanding: | ||||||||||||||||
| Basic | 742,541,052 | 692,623,282 | 712,791,115 | 669,753,458 | ||||||||||||
| Diluted | 742,541,052 | 692,623,282 | 712,791,115 | 669,753,458 |
ROIVANT SCIENCES LTD.
Reconciliation of GAAP to Non-GAAP Financial Measures
(unaudited, in thousands)
| Three Months Ended March 31, | Years Ended March 31, | |||||||||||||||||||
| Note | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Loss from continuing operations, net of tax | $ | (175,423 | ) | $ | (291,313 | ) | $ | (1,230,024 | ) | $ | (924,116 | ) | ||||||||
| Adjustments: | ||||||||||||||||||||
| Cost of revenues | ||||||||||||||||||||
| Amortization of intangibles | (1) | 2,298 | - | 7,468 | - | |||||||||||||||
| Share-based compensation | (2) | 37 | - | 95 | - | |||||||||||||||
| Research and development: | ||||||||||||||||||||
| Share-based compensation | (2) | 4,366 | 16,294 | 30,914 | 63,735 | |||||||||||||||
| Depreciation and amortization | (3) | 1,539 | 943 | 5,097 | 3,244 | |||||||||||||||
| Selling, general and administrative: | ||||||||||||||||||||
| Share-based compensation | (2) | 20,832 | 60,865 | 186,603 | 501,221 | |||||||||||||||
| Depreciation and amortization | (3) | 2,116 | 763 | 6,292 | 2,688 | |||||||||||||||
| Other: | ||||||||||||||||||||
| Change in fair value of investments | (4) | (32,462 | ) | 72,909 | 20,815 | 87,291 | ||||||||||||||
| Gain on sale of investment | (5) | - | - | - | (443,754 | ) | ||||||||||||||
| Change in fair value of debt and liability instruments | (6) | (12,031 | ) | (44,101 | ) | 78,001 | (3,354 | ) | ||||||||||||
| Gain on termination of Sumitomo Options | (7) | - | - | - | (66,472 | ) | ||||||||||||||
| Gain on deconsolidation of subsidiaries | (8) | - | (5,041 | ) | (29,276 | ) | (5,041 | ) | ||||||||||||
| Estimated income tax impact from adjustments | (9) | (704 | ) | 942 | (294 | ) | 313 | |||||||||||||
| Adjusted loss from continuing operations, net of tax (Non-GAAP) | $ | (189,432 | ) | $ | (187,739 | ) | $ | (924,309 | ) | $ | (784,245 | ) |
| Three Months Ended March 31, | Years Ended March 31, | |||||||||||||||||||
| Note | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Research and development expenses | $ | 131,857 | $ | 135,077 | $ | 525,215 | $ | 483,035 | ||||||||||||
| Adjustments: | ||||||||||||||||||||
| Share-based compensation | (2) | 4,366 | 16,294 | 30,914 | 63,735 | |||||||||||||||
| Depreciation and amortization | (3) | 1,539 | 943 | 5,097 | 3,244 | |||||||||||||||
| Adjusted research and development expenses (Non-GAAP) | $ | 125,952 | $ | 117,840 | $ | 489,204 | $ | 416,056 |
| Three Months Ended March 31, | Years Ended March 31, | |||||||||||||||||||
| Note | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Selling, general and administrative expenses | $ | 125,510 | $ | 138,973 | $ | 600,506 | $ | 775,033 | ||||||||||||
| Adjustments: | ||||||||||||||||||||
| Share-based compensation | (2) | 20,832 | 60,865 | 186,603 | 501,221 | |||||||||||||||
| Depreciation and amortization | (3) | 2,116 | 763 | 6,292 | 2,688 | |||||||||||||||
| Adjusted selling, general and administrative expenses (Non-GAAP) | $ | 102,562 | $ | 77,345 | $ | 407,611 | $ | 271,124 |
Notes to non-GAAP financial measures:
(1) Represents non-cash amortization of intangible assets associated with milestone payments made in connection with regulatory
(2) Represents non-cash share-based compensation expense.
(3) Represents non-cash depreciation and amortization expense, other than amortization of intangible assets associated with milestone
payments made in connection with regulatory approvals.
(4) Represents the unrealized loss (gain) on equity investments in unconsolidated entities that are accounted for at fair value with
changes in value reported in earnings.
(5) Represents a one-time gain on sale of investment resulting from the merger of Datavant and CIOX Health in July 2021.
(6) Represents the change in fair value of debt and liability instruments, which is non-cash and primarily includes the unrealized loss
relating to the measurement and recognition of fair value on a recurring basis of certain liabilities.
(7) Represents the one-time gain on termination of the options held by Sumitomo Pharma Co., Ltd. to purchase Roivant's ownership
interest in certain Vants (the "Sumitomo Options").
(8) Represents the one-time gain on deconsolidation of subsidiaries.
(9) Represents the estimated tax effect of the adjustments.
Investor Conference Call Information
Roivant will host a live conference call and webcast at 8:00 a.m. EST on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provide a business update.
To access the conference call by phone, please register online using this registration
link. A webcast of the call will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on
Roivant's website after the conference call.
Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and
commercialization of medicines that matter. Today, Roivant's pipeline is concentrated in inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic
dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor ("FcRn") in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative
colitis and Crohn's disease, in addition to several other therapies in various stages of clinical development. We advance our pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize our medicines and technologies. Beyond
therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit www.roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical
facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually
identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar
expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes,
beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our products and product candidates, the availability and success of topline
results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including